• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

我父亲肺鳞癌的治疗贴(2014年3月1日驾鹤西去)

    [复制链接]
1272735 1620 老马 发表于 2011-10-27 08:05:18 | 置顶 |
老马  博士一年级 发表于 2012-4-27 18:50:42 | 显示全部楼层 来自: 浙江温州
Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type2 W6 M! O( E% n* B4 o4 ~
NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
3 z0 ~3 L' u3 H8 Z+ Author Affiliations
$ a  k: s$ ]* F
' l2 U, t- b% `+ p1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan
6 _. P$ M) ~; k  U7 z( k2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
  `- e3 ?% K+ U: ]# k0 V8 K3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
/ z: r, E+ A3 m/ ~  j4 ?4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
; I$ E8 f& K* x5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
1 Z% a* b9 }5 L* [6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan ! r& T( T+ n1 ?2 {
7Kinki University School of Medicine, Osaka 589-8511, Japan 1 \* _- }3 g7 Y1 y& g$ {
8Izumi Municipal Hospital, Osaka 594-0071, Japan
, j6 n, P2 O) k' J  q9 G9 b9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
  |( C5 @: D" D; Z7 PCorrespondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp + O9 q5 J& B! G# V
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type. , t4 [. M" l4 n* x, Q, L- Q
% y+ L  H4 h8 r0 o! E
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:52:43 | 显示全部楼层 来自: 浙江温州
S-1 monotherapy for previously treated non-small cell lung cancer: A retrospective analysis by age and histopathological type
" ]' Y6 _" n$ b6 e1 C. ?$ u8 _, J0 W( W- c; A2 i* y
Authors: Yuki Tomita, Tetsuya Oguri, Osamu Takakuwa, Makoto Nakao, Eiji Kunii, Takehiro  Uemura, Hiroaki Ozasa, Mikinori Miyazaki, Ken Maeno, Shigeki Sato % ~' |- b9 ?% A6 B( \7 `

4 c1 y+ s' ?  t: f/ JAffiliations: Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan  + Z" X! [% }; `$ D6 r9 e

. c6 m" h- b4 n% ]7 R8 ePublished online on: Thursday, December 1, 2011
1 ^& l* }# S* E' I$ A! e
! R+ I: W  g' IDoi: 10.3892/ol.2011.507 % y' g0 C# i, o2 F% G" b
! d  r# ~) `& }% R
Pages: 405-410 % u7 J& n5 P3 B  _
! s( w- ^; h% r3 H; }+ B
Abstract:
! _2 m2 L. [  ~' H1 l/ N3 G7 ZS-1, an oral fluoropyrimidine derivative, has been approved for the treatment of non-small cell lung cancer (NSCLC) in Japan. In the present study, the efficacy and safety of S-1 monotherapy for elderly patients with previously treated NSCLC were retrospectively evaluated, and the efficacy of S-1 monotherapy was compared by histopathological type. This retrospective study included 54 patients with advanced or recurrent NSCLC who had received S-1 monotherapy following the failure of previous chemotherapy regimens at our institutes. Patient outcomes were compared based on their age and histopathological type. S-1 was administered orally, twice daily, while the duration and interval were modified according to the medical condition of each patient. The default delivery schedule, the mean number of S-1 cycles, did not differ significantly between the two age groups (<70 and ≥70 years). The rate of therapy discontinuation, schedule modification or dose reduction due to intolerable toxicities or patient refusal was relatively frequent in the older group (40.7 and 55.6% for ages <70 and ≥70 years, respectively; p=0.414), and the incidence of grade 3 anemia was relatively high in the older group (3.7 and 18.5%, respectively; p=0.192). The response rates (13.0 and 4.8%, respectively; p=0.609) and disease control rates (39.1 and 33.3%, respectively; p=0.761) did not differ significantly between the two age groups. According to histopathological type, the disease control rate was significantly higher in adenocarcinoma (57.9%) compared to non-adenocarcinoma (20.0%, p=0.013). Thus, S-1 monotherapy may be equally effective and tolerated in patients <70 years and those ≥70 years. Additionally, adenocarcinoma may have a higher disease control rate than non-adenocarcinoma.* m" |: \! ^2 a  c9 Y

7 X! r/ M  y: J4 T, s0 ]4 b( Y$ {
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:57:27 | 显示全部楼层 来自: 浙江温州
Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population
* q! Q# E7 l% a' L2 lF. Tanaka1,*, H. Wada2, Y. Fukui3 and M. Fukushima3 $ u( c  X% L7 D7 X7 X
+ Author Affiliations/ X& t* n) S1 S% l$ I& E4 t
1Second Department of Surgery, University of Environmental and Occupational Health, Kitakakyushu   B5 ^* r& f6 [9 w% K% Y
2Department of Thoracic Surgery, Kyoto University, Kyoto
/ Y- ^$ X3 T8 {0 L! Z3Tokushima Research Center, Taiho Pharmaceutical Co. Ltd, Tokushima, Japan . N4 Y7 M/ P- J6 U; _+ ^- w$ A
&#8629;*Correspondence to: Dr F. Tanaka, Second Department of Surgery, University of Environmental and Occupational Health, 1-1 Isegaoka, Yahata-nishi, Kitakakyushu, 807-8555, Japan. Tel: +81-93-891-7442; Fax: +81-93-692-4004; E-mail: ftanaka@med.uoeh-u.ac.jp
  T+ Z8 Q; F, d+ p( ?Received September 3, 2010.
$ r; z! V7 V% sRevision received November 11, 2010. 9 M1 E6 _+ Y. q8 Q- [$ K9 D
Accepted November 17, 2010. 5 e9 Y! n; S0 u# S- t, q& K% j5 |
Abstract
* C" \% @  l- VBackground: Previous small-sized studies showed lower thymidylate synthase (TS) expression in adenocarcinoma of the lung, which may explain higher antitumor activity of TS-inhibiting agents such as pemetrexed.
( D; s6 n* K* }# g4 {' iPatients and methods: To quantitatively measure TS gene expression in a large-scale Japanese population (n = 2621) with primary lung cancer, laser-captured microdissected sections were cut from primary tumors, surrounding normal lung tissues and involved nodes.
, v) e) l& ?  g/ f9 ?Results: TS gene expression level in primary tumor was significantly higher than that in normal lung tissue (mean TS/β-actin, 3.4 and 1.0, respectively; P < 0.01), and TS gene expression level was further higher in involved node (mean TS/β-actin, 7.7; P < 0.01). Analyses of TS gene expression levels in primary tumor according to histologic cell type revealed that small-cell carcinoma showed highest TS expression (mean TS/β-actin, 13.8) and that squamous cell carcinoma showed higher TS expression as compared with adenocarcinoma (mean TS/β-actin, 4.3 and 2.3, respectively; P < 0.01); TS gene expression was significantly increased along with a decrease in the grade of tumor cell differentiation. There was no significant difference in TS gene expression according to any other patient characteristics including tumor progression.
5 ^! l% F: y5 I; c( B$ c! O- qConclusion: Lower TS expression in adenocarcinoma of the lung was confirmed in a large-scale study. 4 v5 Z' D7 t2 E  k
个人公众号:treeofhope
走在异乡  高中一年级 发表于 2012-4-28 00:30:22 | 显示全部楼层 来自: 四川成都
一直关注老马的帖子,前方的指明灯。祝福你爸好疗效
累计签到:1 天
连续签到:1 天
[LV.1]初来乍到
baiselianyi  初中二年级 发表于 2012-4-28 10:24:44 | 显示全部楼层 来自: 浙江台州
一直得到老马帮助,祝福老马爸爸
老马  博士一年级 发表于 2012-4-28 18:00:37 | 显示全部楼层 来自: 浙江温州
26日吃了12片地米(0.75mg一片),27日吃了22片地米(0.75mg 一片),28日吃了12片地米(0.75mg一片),都分二次吃。
! r7 U# \* t% ~/ c, e1 b, F( ~今天为止没有任何反应,每天吃VC,VB2,还有漱口水,就怕口腔溃疡。
个人公众号:treeofhope
bishop_cn  大学一年级 发表于 2012-4-28 23:16:11 | 显示全部楼层 来自: 中国
副作用如何,单药反应很小吧?
: N( ~6 c0 \1 P& a
老马  博士一年级 发表于 2012-4-29 00:20:00 | 显示全部楼层 来自: 浙江温州
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy' m6 o* t' K" u- [1 i: n
http://clinicaltrials.gov/ct2/show/NCT01523587
7 L; D7 i1 b3 M5 U* n* |  U8 E# V( r9 j( i) Z4 U- z+ f
BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC0 W  ^+ D& e' c0 Y% H
http://clinicaltrials.gov/ct2/show/NCT01156545
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-29 20:53:58 | 显示全部楼层 来自: 浙江温州
本帖最后由 老马 于 2012-4-30 09:33 编辑
% g6 q* e0 ?* R' m- N3 \& s5 f% F& U: J8 D! ?
从4月24日开始到4月28日,打了5天的舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。$ v  M3 A' [! R0 m  \
至今为止,未出现化疗副作用。
个人公众号:treeofhope
英雄武松  大学四年级 发表于 2012-4-30 01:37:05 | 显示全部楼层 来自: 哈萨克斯坦
老马 发表于 2012-4-29 20:53
- H7 I0 ?+ Y7 i, L2 F从4月24日开始到4月28日,打了5天的打了5天舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。5 j  z$ |( ?( s' i" Q. {5 r& C
至今为止,未出 ...

  T4 O! @5 c  c, h+ D没有副作用是第一追求,效果显著是第二追求。& d' c2 m, Y/ S+ p5 n( f1 T% I
不错。

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表